skip to main content

Benign prostatic enlargement with recurrent urinary tract infection — MSRA MCQ

Instant feedback + full explanation. One question, done properly.

ModerateBPHBenign prostatic enlargement with recurrent urinary tract infectionMSRA

A 74-year-old man with benign prostatic enlargement has taken tamsulosin MR 400 micrograms daily for 10 months, with improved hesitancy and weak stream. During the past 5 months, he has had two separate episodes of dysuria and frequency, each with a positive midstream urine culture and symptom resolution following culture-directed antibiotics. He is currently asymptomatic. Urine dipstick is negative for blood, leucocytes and nitrites. eGFR is 76 mL/min/1.73 m². Digital rectal examination shows a smooth enlarged prostate. There is no visible haematuria, loin pain, fever, palpable bladder, weight loss or neurological abnormality. What is the most appropriate next management step?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Refer for specialist urological assessment

Explanation lettering: D = shown as A · A = shown as B · E = shown as D · B = shown as E

This man has recurrent UTI, defined as at least 2 proven infections within 6 months. In a man with LUTS due to benign prostatic enlargement, recurrent or persistent UTI is a complication requiring specialist assessment, even when symptoms have settled and renal function is currently preserved. The referral allows assessment for clinically relevant bladder outlet obstruction, incomplete emptying, stones or other structural pathology; flow rate and post-void residual measurement are part of specialist assessment, with imaging or cystoscopy directed by the clinical findings. A is initially attractive because prophylaxis can reduce recurrence in selected patients, but recurrent UTI in a man should first prompt specialist assessment rather than empiric long-term prophylaxis. B may reduce future BPH progression in an appropriate man with an enlarged prostate, but does not address recurrent infection as a complication requiring referral. C includes investigations that may be relevant later, but NICE does not recommend routine flow-rate measurement, residual-volume measurement or upper-tract imaging at initial assessment; these are undertaken selectively in specialist care. D is inappropriate because recurrent infection alone, without haematuria, abnormal DRE, concerning PSA features or other cancer indicators, does not establish a suspected-cancer pathway indication.

Reference: NICE CG97: Lower urinary tract symptoms in men: management — Recommendations (Last reviewed 19 December 2024) — https://www.nice.org.uk/guidance/cg97/chapter/recommendations NICE CG97: Lower urinary tract symptoms in men: management — Recommendations (Last reviewed 19 December 2024) — https://www.nice.org.uk/guidance/cg97/chapter/recommendations NICE Quality Standard QS90: Referring adults with recurrent urinary tract infection (Updated 2023) — https://www.nice.org.uk/guidance/qs90/chapter/quality-statement-5-referring-adults-with-recurrent-urinary-tract-infection